Why the study?
Does concurrent administration of cholestyramine alter the pharmacokinetics of naproxen in healthy volunteers?
Does concurrent administration of cholestyramine alter the pharmacokinetics of naproxen in healthy volunteers?
Concurrent administration of cholestyramine delays the absorption of naproxen but does not alter its overall pharmacokinetics.
May delay naproxen absorption with cholestyramine; leaves open clinical relevance and need for outcome studies.
'In vitro' and 'in vivo' studies were used to determine the interaction of naproxen, an anti-inflammatory agent, and cholestyramine, a hypocholesterolemic substance. Cholestyramine shows a marked affinity for naproxen and the intensity of this is governed by the pH values. The maximum amount of naproxen adsorbed by the resin is close to 2.2 mM g-1. The pharmacokinetics of naproxen was studied in eight healthy volunteers after concurrent oral administration in a single dose of 250 mg of naproxen and 4 g of cholestyramine. The resin causes an important delay in the incorporation of naproxen into the systemic circulation, though no significant modifications are seen to take place in any other pharmacokinetic parameters of the drug.
No takes yet. Share an insight, caveat, or question.
Calvo et al. (1984) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: